KNUST COVID-19 CLINICAL TRIAL

Repurposing the aqueous extract of cryptolepis for COVID-19 immunotherapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202010690466874

Enrollment

Registered

2020-10-07

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVD-19

Interventions

Nibima

Drinking water

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Provision of signed and dated informed consent form. Stated willingness to comply with all study procedures and availability for the duration of the study. Male or female, aged 18 or above. Covid-19 laboratory confirmed. Ability to take oral medication and be willing to adhere to the study inter-vention regimen.

Exclusion criteria

Exclusion criteria: Presence of <specific devices (e.g., cardiac pacemaker). Pregnancy or lactation. Known allergic reactions to components of the study intervention (C. san-guinolenta). Treatment with another investigational drug other than the current Covid-19 standard therapy. Treatment with herbal medicine in the past 4 weeks. Current smoker. Mentally unstable

Design outcomes

Primary

Measure	Time frame
1.Covid-19 viral load/patient reduced by >50% over a period of 14 days. 2.Improvements in Covid-19 clinical recovery rate by 50% over a period of 14 days.	—

Secondary

Measure	Time frame
Study intervention will effectively and safely progress and there will be no need to prematurely stop the study.	—

Countries

Ghana

Contacts

Public ContactMohamed Mutocheluh

Associate Professor

mutocheluh@gmail.com00233200504700

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026